Revelation Biosciences Inc   (REVB)
Other Ticker:  
Price: $3.4300 $0.27 8.544%
Day's High: $3.4799 Week Perf: 8.89 %
Day's Low: $ 3.03 30 Day Perf: -65.23 %
Volume (M): 341 52 Wk High: $ 67.20
Volume (M$): $ 1,169 52 Wk Avg: $24.29
Open: $3.16 52 Wk Low: $2.40

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 0

Revelation Biosciences Inc
Revelation Biosciences Inc is a biotechnology company that focuses on the development of innovative therapies for various diseases. The company specializes in the discovery and development of small molecule drugs and biologics targeting a range of therapeutic areas, including inflammation, immunology, and oncology. They employ state-of-the-art technologies and a multidisciplinary approach to accelerate the development of novel treatments. Revelation Biosciences aims to address the unmet medical needs of patients through their research and discovery efforts.

   Company Address: 4660 La Jolla Village Drive San Diego 92122 CA
   Company Phone Number: 800-3717   Stock Exchange / Ticker: NASDAQ REVB
   REVB is expected to report next financial results on March 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Revelation Biosciences Inc. to Present Groundbreaking Preclinical Data on Gemini for Acute Kidney Injury Prevention at Prestigious International Conference

Published Tue, Feb 13 2024 2:00 PM UTC

Revelation Biosciences Inc. (NASDAQ: REVB), a leading biotech company focused on innovative treatments for critical conditions, has received a prestigious invitation to deliver an oral presentation at The 29th International Conference on Advances in Critical Care Nephrology. The conference, commonly known as AKI & CRRT 2024, will be held in San Diego from March 12-15, 2024. ...

Stock Issue News

Revelation Biosciences Inc. Completes $6.2 Million Public Offering, Paving the Way for Trained Immunity Research

Published Mon, Feb 5 2024 9:41 PM UTC

Revelation Biosciences Inc. Successfully Completes Public Offering, Raising $6.2 Million for Advancement in Trained Immunity Research
SAN DIEGO - Revelation Biosciences Inc. (NASDAQ: REVB), a pioneering life sciences company dedicated to harnessing the potential of trained immunity in the prevention and treatment of diseases, proudly announced the successful closing of i...

Financing Agreement

Revelation Biosciences Inc. Raises $6.2 Million in Public Offering Amid Leverage Ratio Concerns

Published Thu, Feb 1 2024 11:00 AM UTC

Revelation Biosciences Inc. Announces Pricing of Public Offering and Addresses Leverage Ratio Concerns
San Diego, CA - In a press release issued today, Revelation Biosciences Inc. (NASDAQ: REVB), a life sciences company focused on utilizing trained immunity for disease prevention and treatment, announced the pricing of a public offering of 1,365,000 shares of its common ...

Revelation Biosciences Inc

Revelation Biosciences Inc. Encounters Escalating Working Expenses During Third Quarter of 2023 Earnings Season

Experts in the Major Pharmaceutical Preparations industry have begun analyzing the financial results for Revelation Biosciences Inc's third quarter of 2023. The company reported an operating deficit of $-2.777897 million for the quarter, but did not disclose any top-line figures. Comparatively, the operating deficit for the same period in 2022 was $-1.199464 million. Additionally, the company's net loss for the emerging cycle increased from $-1.171 million in the third quarter of 2022 to $-2.628 million in the third quarter of 2023. This article aims to provide an overview of the company's financial performance and put it into context.
Financial Performance Analysis:
Revelation Biosciences Inc's third quarter financial results for 2023 indicate a significant increase in the operating deficit compared to the previous year. The company's efforts to contextualize these earnings point to potential challenges faced during this period. It is evident that the management is actively searching for various financial plans to stabilize the business and improve performance.

Revelation Biosciences Inc

Revelation Biosciences Inc Faces Challenges with Diminishing Returns, Continuing Operating Loss, and Share Drop

Revelation Biosciences Inc, a major player in the pharmaceutical preparations sector, has experienced a drop in shares over the past week, contributing to an impressive year-to-date performance. However, despite this, the company faces challenges as it reports a continuing operating loss and diminishing returns. As investors and industry advisors consider the implications of these financial results, it is crucial to assess how they may impact Revelation Biosciences Inc going forward.
Share Performance:
Over the past seven days, Revelation Biosciences Inc shares have dropped by -7.71%. While this recent decline may be concerning for investors, it is essential to note that the company has still achieved a remarkable year-to-date performance of 293.04%. However, the shares are currently trading on the NASDAQ at -19.6% below its 52-week average, indicating potential concerns in the market.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com